Cassaday & Co Wealth Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Cassaday & Co Wealth Management’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48K	Hold	26	–	–	﹤0.01%	1049
2026 Q1	$1.14K	Buy	+26	New	+$1.2K	﹤0.01%	1116

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Cassaday & Co Wealth Management's GNOM Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q2 2026 at 26 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Cassaday & Co Wealth Management first reported a position in GNOM in Q1 2026 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Cassaday & Co Wealth Management held 26 shares of Global X Genomics & Biotechnology ETF worth $1.48K as of Q2 2026.
Cassaday & Co Wealth Management left its Global X Genomics & Biotechnology ETF share count unchanged in Q2 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1049 holding.
Cassaday & Co Wealth Management first reported a position in Global X Genomics & Biotechnology ETF in Q1 2026 and has held it in 2 quarters since.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.